B-cell lymphoma refers to types of non-Hodgkin lymphoma that are characterized by abnormalities of the "B-cells" (a type of white blood cell that makes antibodies to help fight infection). The condition may grow and spread slowly with few symptoms (also known as indolent lymphoma) or may be very aggressive with severe symptoms.
Disease: B-cell Malignancy; Non-Hodgkin Lymphoma; B-cell Lymphoma
Study Director: Ewelina Morawa, MD
United States, Illinois
United States, Kansas
United States, Oregon
United States, Tennessee
Australia, New South Wales
Status: Active recruiting
This is a single-arm, open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX110 in subjects with relapsed or refractory B-cell malignancies.
CTX110 CD19-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components.
CTX110 is an allogeneic CRISPR-Cas9 gene-edited CAR-T cell therapy targeting CD19 for the treatment of CD19+ malignancies.